Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kenneth Carl Anderson, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Anderson and Paul Richardson.
Connection Strength

50.209
  1. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018 11 09; 8(11):109.
    View in: PubMed
    Score: 0.810
  2. Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol. 2018 May; 14(11):1035-1047.
    View in: PubMed
    Score: 0.762
  3. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 06 02; 127(22):2693-700.
    View in: PubMed
    Score: 0.675
  4. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):255-61.
    View in: PubMed
    Score: 0.615
  5. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
    View in: PubMed
    Score: 0.580
  6. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32.
    View in: PubMed
    Score: 0.580
  7. IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. Oncology (Williston Park). 2013 Aug; 27(8):803-4, 806.
    View in: PubMed
    Score: 0.562
  8. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul; 37(7):829-37.
    View in: PubMed
    Score: 0.550
  9. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
    View in: PubMed
    Score: 0.538
  10. Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May; 8(5):623-33.
    View in: PubMed
    Score: 0.515
  11. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
    View in: PubMed
    Score: 0.510
  12. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
    View in: PubMed
    Score: 0.500
  13. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
    View in: PubMed
    Score: 0.496
  14. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011 Sep; 154(6):745-54.
    View in: PubMed
    Score: 0.488
  15. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
    View in: PubMed
    Score: 0.487
  16. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
    View in: PubMed
    Score: 0.483
  17. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011 Jun; 153(6):729-40.
    View in: PubMed
    Score: 0.480
  18. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79.
    View in: PubMed
    Score: 0.471
  19. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010 Aug; 150(4):438-45.
    View in: PubMed
    Score: 0.454
  20. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010 Aug; 150(4):428-37.
    View in: PubMed
    Score: 0.454
  21. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
    View in: PubMed
    Score: 0.452
  22. The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
    View in: PubMed
    Score: 0.449
  23. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
    View in: PubMed
    Score: 0.447
  24. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
    View in: PubMed
    Score: 0.443
  25. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw. 2010 Feb; 8 Suppl 1:S4-S12.
    View in: PubMed
    Score: 0.441
  26. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
    View in: PubMed
    Score: 0.431
  27. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23; 114(4):772-8.
    View in: PubMed
    Score: 0.420
  28. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
    View in: PubMed
    Score: 0.395
  29. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15; 110(10):3557-60.
    View in: PubMed
    Score: 0.371
  30. New drugs for myeloma. Oncologist. 2007 Jun; 12(6):664-89.
    View in: PubMed
    Score: 0.366
  31. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007 Jun; 137(5):429-35.
    View in: PubMed
    Score: 0.363
  32. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw. 2007 Feb; 5(2):149-62.
    View in: PubMed
    Score: 0.358
  33. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
    View in: PubMed
    Score: 0.356
  34. Can thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol. 2006 Nov; 3(11):590-1.
    View in: PubMed
    Score: 0.352
  35. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006 Nov; 18(6):598-608.
    View in: PubMed
    Score: 0.352
  36. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2006 Aug; 6(8):1165-73.
    View in: PubMed
    Score: 0.346
  37. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64.
    View in: PubMed
    Score: 0.345
  38. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer. 2006 Mar 15; 106(6):1316-9.
    View in: PubMed
    Score: 0.337
  39. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006; 57:33-47.
    View in: PubMed
    Score: 0.332
  40. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol. 2006 Jan 20; 24(3):334-6.
    View in: PubMed
    Score: 0.331
  41. New treatments for multiple myeloma. Oncology (Williston Park). 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7.
    View in: PubMed
    Score: 0.330
  42. Emerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma. 2005 Sep; 6(2):84-8.
    View in: PubMed
    Score: 0.325
  43. Proteasome inhibition in the treatment of cancer. . 2005 Feb; 4(2):290-6.
    View in: PubMed
    Score: 0.312
  44. Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol. 2005; 18(4):619-34.
    View in: PubMed
    Score: 0.310
  45. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol. 2004 Aug 15; 22(16):3212-4.
    View in: PubMed
    Score: 0.300
  46. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004 Jul; 79(7):875-82.
    View in: PubMed
    Score: 0.299
  47. An update of novel therapeutic approaches for multiple myeloma. Curr Treat Options Oncol. 2004 Jun; 5(3):227-38.
    View in: PubMed
    Score: 0.298
  48. Proteasome inhibition in hematologic malignancies. Ann Med. 2004; 36(4):304-14.
    View in: PubMed
    Score: 0.289
  49. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol. 2003 Oct; 1(10):596-600.
    View in: PubMed
    Score: 0.284
  50. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003 Sep-Oct; 10(5):361-9.
    View in: PubMed
    Score: 0.283
  51. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26; 348(26):2609-17.
    View in: PubMed
    Score: 0.279
  52. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 Nov 01; 100(9):3063-7.
    View in: PubMed
    Score: 0.267
  53. Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002; 53:629-57.
    View in: PubMed
    Score: 0.252
  54. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2021 Jul 21.
    View in: PubMed
    Score: 0.244
  55. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 Jun; 7(23).
    View in: PubMed
    Score: 0.242
  56. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep; 2(5):468-483.
    View in: PubMed
    Score: 0.240
  57. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.
    View in: PubMed
    Score: 0.238
  58. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 03 01; 39(7):757-767.
    View in: PubMed
    Score: 0.234
  59. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 09 04; 10(9):91.
    View in: PubMed
    Score: 0.230
  60. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020 May; 7(5):e395-e407.
    View in: PubMed
    Score: 0.223
  61. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
    View in: PubMed
    Score: 0.215
  62. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 06; 20(6):781-794.
    View in: PubMed
    Score: 0.210
  63. Correction: Dual Inhibition of Canonical and Noncanonical NF-?B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clin Cancer Res. 2019 May 01; 25(9):2938.
    View in: PubMed
    Score: 0.209
  64. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019 07 11; 134(2):123-133.
    View in: PubMed
    Score: 0.207
  65. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226.
    View in: PubMed
    Score: 0.207
  66. The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018 12; 15(12):1033-1052.
    View in: PubMed
    Score: 0.203
  67. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019 02; 33(2):426-438.
    View in: PubMed
    Score: 0.199
  68. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 Aug; 16(8):564-574.
    View in: PubMed
    Score: 0.199
  69. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018 08; 182(4):495-503.
    View in: PubMed
    Score: 0.196
  70. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):433-446.
    View in: PubMed
    Score: 0.196
  71. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; 32(9):1932-1947.
    View in: PubMed
    Score: 0.193
  72. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opin Pharmacother. 2017 Dec; 18(18):1975-1985.
    View in: PubMed
    Score: 0.190
  73. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017 12; 36(4):561-584.
    View in: PubMed
    Score: 0.190
  74. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep; 178(6):896-905.
    View in: PubMed
    Score: 0.184
  75. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017 08; 178(4):547-560.
    View in: PubMed
    Score: 0.182
  76. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319.
    View in: PubMed
    Score: 0.178
  77. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341.
    View in: PubMed
    Score: 0.177
  78. Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5688-5695.
    View in: PubMed
    Score: 0.171
  79. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 06 23; 127(25):3225-36.
    View in: PubMed
    Score: 0.170
  80. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016 08; 174(3):397-409.
    View in: PubMed
    Score: 0.170
  81. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258.
    View in: PubMed
    Score: 0.166
  82. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50.
    View in: PubMed
    Score: 0.166
  83. Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015; 10(12):e0143847.
    View in: PubMed
    Score: 0.165
  84. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec; 2(12):e516-27.
    View in: PubMed
    Score: 0.165
  85. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. Br J Haematol. 2015 Dec; 171(5):798-812.
    View in: PubMed
    Score: 0.164
  86. Promising therapies in multiple myeloma. Blood. 2015 Jul 16; 126(3):300-10.
    View in: PubMed
    Score: 0.159
  87. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
    View in: PubMed
    Score: 0.159
  88. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
    View in: PubMed
    Score: 0.159
  89. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol. 2015; 11(8):1153-68.
    View in: PubMed
    Score: 0.155
  90. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015 Jan; 12(1):42-54.
    View in: PubMed
    Score: 0.154
  91. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015 Jan; 100(1):100-6.
    View in: PubMed
    Score: 0.152
  92. Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):903-25.
    View in: PubMed
    Score: 0.151
  93. The challenge of cross-trial comparisons using limited data. Haematologica. 2014 Aug; 99(8):e145-6.
    View in: PubMed
    Score: 0.151
  94. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014 Aug 15; 74(16):4458-69.
    View in: PubMed
    Score: 0.149
  95. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014 Jul 10; 32(20):2125-32.
    View in: PubMed
    Score: 0.149
  96. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15; 123(20):3128-38.
    View in: PubMed
    Score: 0.146
  97. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014 Apr; 23(4):445-52.
    View in: PubMed
    Score: 0.146
  98. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014 Jan 30; 123(5):706-16.
    View in: PubMed
    Score: 0.144
  99. Clinical translation in multiple myeloma: from bench to bedside. Semin Oncol. 2013 Oct; 40(5):549-53.
    View in: PubMed
    Score: 0.142
  100. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013 Oct 10; 31(29):3696-703.
    View in: PubMed
    Score: 0.142
  101. Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013 Aug 15; 122(7):1243-55.
    View in: PubMed
    Score: 0.140
  102. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun 01; 19(11):3019-31.
    View in: PubMed
    Score: 0.138
  103. Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood. 2013 Jan 31; 121(5):858.
    View in: PubMed
    Score: 0.136
  104. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11; 121(15):2975-87.
    View in: PubMed
    Score: 0.135
  105. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des. 2013; 19(4):734-44.
    View in: PubMed
    Score: 0.135
  106. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
    View in: PubMed
    Score: 0.134
  107. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013 Feb 01; 31(4):448-55.
    View in: PubMed
    Score: 0.134
  108. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012 Dec; 7(4):258-66.
    View in: PubMed
    Score: 0.134
  109. Sequence analysis of ß-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012 Nov 29; 120(23):4513-6.
    View in: PubMed
    Score: 0.132
  110. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 08; 120(19):3958-67.
    View in: PubMed
    Score: 0.132
  111. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58.
    View in: PubMed
    Score: 0.132
  112. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29.
    View in: PubMed
    Score: 0.132
  113. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012; 4:253-68.
    View in: PubMed
    Score: 0.131
  114. How I treat plasma cell leukemia. Blood. 2012 Sep 20; 120(12):2376-89.
    View in: PubMed
    Score: 0.131
  115. Dual inhibition of canonical and noncanonical NF-?B pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012 Sep 01; 18(17):4669-81.
    View in: PubMed
    Score: 0.131
  116. Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. J Clin Oncol. 2012 Jul 10; 30(20):e175-9.
    View in: PubMed
    Score: 0.130
  117. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87.
    View in: PubMed
    Score: 0.130
  118. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug; 158(4):472-80.
    View in: PubMed
    Score: 0.129
  119. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol. 2012 Jun; 157(6):718-31.
    View in: PubMed
    Score: 0.129
  120. Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14; 119(24):5772-81.
    View in: PubMed
    Score: 0.129
  121. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43.
    View in: PubMed
    Score: 0.127
  122. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
    View in: PubMed
    Score: 0.127
  123. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012 Jun 01; 30(16):1960-5.
    View in: PubMed
    Score: 0.127
  124. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011 Nov; 10(11):2034-42.
    View in: PubMed
    Score: 0.124
  125. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
    View in: PubMed
    Score: 0.124
  126. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br J Haematol. 2011 Dec; 155(5):588-98.
    View in: PubMed
    Score: 0.124
  127. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2011 Dec; 52(12):2308-15.
    View in: PubMed
    Score: 0.123
  128. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15; 17(16):5311-21.
    View in: PubMed
    Score: 0.122
  129. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43.
    View in: PubMed
    Score: 0.121
  130. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011 May 10; 29(14):1916-23.
    View in: PubMed
    Score: 0.120
  131. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood. 2011 May 26; 117(21):5692-700.
    View in: PubMed
    Score: 0.119
  132. Hematology: Setting the standard for newly diagnosed multiple myeloma. Nat Rev Clin Oncol. 2011 May; 8(5):255-6.
    View in: PubMed
    Score: 0.119
  133. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol. 2011 Apr; 153(2):212-21.
    View in: PubMed
    Score: 0.119
  134. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
    View in: PubMed
    Score: 0.119
  135. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011 Feb; 4(1):51-60.
    View in: PubMed
    Score: 0.118
  136. Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):17-22.
    View in: PubMed
    Score: 0.118
  137. Multiple myeloma. Annu Rev Med. 2011; 62:249-64.
    View in: PubMed
    Score: 0.117
  138. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 02; 116(23):4906-15.
    View in: PubMed
    Score: 0.115
  139. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37.
    View in: PubMed
    Score: 0.114
  140. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8.
    View in: PubMed
    Score: 0.113
  141. Kidney disease associated with plasma cell dyscrasias. Blood. 2010 Sep 02; 116(9):1397-404.
    View in: PubMed
    Score: 0.112
  142. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13.
    View in: PubMed
    Score: 0.112
  143. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5.
    View in: PubMed
    Score: 0.111
  144. The evolution and impact of therapy in multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S1-6.
    View in: PubMed
    Score: 0.111
  145. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010 Feb 01; 16(3):1033-41.
    View in: PubMed
    Score: 0.110
  146. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2010 Jan 28; 115(4):834-45.
    View in: PubMed
    Score: 0.109
  147. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23.
    View in: PubMed
    Score: 0.108
  148. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
    View in: PubMed
    Score: 0.108
  149. Hematology: Thalidomide maintenance in multiple myeloma. Nat Rev Clin Oncol. 2009 Oct; 6(10):565-6.
    View in: PubMed
    Score: 0.108
  150. Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
    View in: PubMed
    Score: 0.107
  151. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2009 Nov; 147(4):531-4.
    View in: PubMed
    Score: 0.107
  152. Multiple myeloma. Lancet. 2009 Jul 25; 374(9686):324-39.
    View in: PubMed
    Score: 0.106
  153. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
    View in: PubMed
    Score: 0.106
  154. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37.
    View in: PubMed
    Score: 0.105
  155. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009 Jul 30; 114(5):1046-52.
    View in: PubMed
    Score: 0.105
  156. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009 May; 50(5):694-702.
    View in: PubMed
    Score: 0.105
  157. Maximizing the clinical benefit of novel therapies in multiple myeloma. Oncology (Williston Park). 2009 Apr 30; 23(5):415-6, 419.
    View in: PubMed
    Score: 0.105
  158. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
    View in: PubMed
    Score: 0.104
  159. Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood. 2009 May 21; 113(21):5228-36.
    View in: PubMed
    Score: 0.104
  160. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar; 14(1):99-127.
    View in: PubMed
    Score: 0.103
  161. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009 Feb 15; 15(4):1210-21.
    View in: PubMed
    Score: 0.103
  162. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009 Mar; 144(6):895-903.
    View in: PubMed
    Score: 0.103
  163. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 2008 Nov; 143(4):511-9.
    View in: PubMed
    Score: 0.101
  164. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov; 143(4):537-40.
    View in: PubMed
    Score: 0.100
  165. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008 Oct 10; 26(29):4784-90.
    View in: PubMed
    Score: 0.100
  166. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25.
    View in: PubMed
    Score: 0.099
  167. Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Clin Pract Oncol. 2008 Jul; 5(7):374-5.
    View in: PubMed
    Score: 0.098
  168. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
    View in: PubMed
    Score: 0.097
  169. Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol. 2008 May; 141(5):659-71.
    View in: PubMed
    Score: 0.097
  170. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008 Mar; 49(3):502-7.
    View in: PubMed
    Score: 0.096
  171. Re: When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2008 Mar 05; 100(5):373.
    View in: PubMed
    Score: 0.096
  172. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag. 2008 Feb; 4(1):129-36.
    View in: PubMed
    Score: 0.096
  173. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 2007 Dec; 20(4):597-612.
    View in: PubMed
    Score: 0.095
  174. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol. 2007 Dec; 20(4):797-816.
    View in: PubMed
    Score: 0.095
  175. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1007-34, vii-viii.
    View in: PubMed
    Score: 0.095
  176. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008 Feb 01; 111(3):1654-64.
    View in: PubMed
    Score: 0.095
  177. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb; 22(2):231-9.
    View in: PubMed
    Score: 0.094
  178. Novel therapies in myeloma. Curr Opin Hematol. 2007 Nov; 14(6):609-15.
    View in: PubMed
    Score: 0.094
  179. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol. 2007 Oct; 139(1):55-63.
    View in: PubMed
    Score: 0.094
  180. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37.
    View in: PubMed
    Score: 0.094
  181. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007 Sep; 138(6):783-91.
    View in: PubMed
    Score: 0.093
  182. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007 Aug; 7(8):585-98.
    View in: PubMed
    Score: 0.093
  183. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68.
    View in: PubMed
    Score: 0.092
  184. Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park). 2007 Jun; 21(7):785-92; discussion 798-800.
    View in: PubMed
    Score: 0.092
  185. Does maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol. 2007 Jul; 4(7):394-5.
    View in: PubMed
    Score: 0.092
  186. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63.
    View in: PubMed
    Score: 0.091
  187. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2007 Apr; 7(4):551-66.
    View in: PubMed
    Score: 0.091
  188. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007 Mar; 12(1):155-63.
    View in: PubMed
    Score: 0.090
  189. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007 Apr 15; 109(8):3177-88.
    View in: PubMed
    Score: 0.089
  190. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol. 2007 Feb; 136(3):414-23.
    View in: PubMed
    Score: 0.089
  191. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 01; 109(3):1220-7.
    View in: PubMed
    Score: 0.088
  192. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets. 2006 Oct; 7(10):1341-7.
    View in: PubMed
    Score: 0.087
  193. Recent advances in the treatment of Multiple Myeloma. Curr Pharm Biotechnol. 2006 Oct; 7(5):381-93.
    View in: PubMed
    Score: 0.087
  194. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94.
    View in: PubMed
    Score: 0.087
  195. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82.
    View in: PubMed
    Score: 0.086
  196. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73.
    View in: PubMed
    Score: 0.086
  197. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 01; 24(19):3113-20.
    View in: PubMed
    Score: 0.086
  198. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704.
    View in: PubMed
    Score: 0.084
  199. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006 Feb; 132(4):385-97.
    View in: PubMed
    Score: 0.084
  200. Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opin Investig Drugs. 2006 Feb; 15(2):171-9.
    View in: PubMed
    Score: 0.084
  201. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006 May 15; 107(10):4053-62.
    View in: PubMed
    Score: 0.083
  202. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006 Jan 01; 66(1):184-91.
    View in: PubMed
    Score: 0.083
  203. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20.
    View in: PubMed
    Score: 0.083
  204. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005 Nov 15; 104(10):2141-8.
    View in: PubMed
    Score: 0.082
  205. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005 Nov; 8(5):407-19.
    View in: PubMed
    Score: 0.082
  206. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100.
    View in: PubMed
    Score: 0.082
  207. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005 Sep 15; 65(18):8350-8.
    View in: PubMed
    Score: 0.081
  208. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol. 2005 Sep 10; 23(26):6345-50.
    View in: PubMed
    Score: 0.081
  209. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005 Aug 15; 65(16):7478-84.
    View in: PubMed
    Score: 0.081
  210. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005 Nov 01; 106(9):2977-81.
    View in: PubMed
    Score: 0.080
  211. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 Jul 01; 65(13):5898-906.
    View in: PubMed
    Score: 0.080
  212. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16; 352(24):2487-98.
    View in: PubMed
    Score: 0.080
  213. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005 Jun 14; 102(24):8567-72.
    View in: PubMed
    Score: 0.080
  214. Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Rev Anticancer Ther. 2005 Jun; 5(3):465-76.
    View in: PubMed
    Score: 0.080
  215. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood. 2005 Sep 01; 106(5):1794-800.
    View in: PubMed
    Score: 0.079
  216. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene. 2005 Apr 28; 24(19):3121-9.
    View in: PubMed
    Score: 0.079
  217. Proteasome inhibitor therapy in multiple myeloma. . 2005 Apr; 4(4):686-92.
    View in: PubMed
    Score: 0.079
  218. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6.
    View in: PubMed
    Score: 0.078
  219. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005 Jan 20; 23(3):630-9.
    View in: PubMed
    Score: 0.078
  220. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203.
    View in: PubMed
    Score: 0.077
  221. Proteasome inhibitors as therapeutics. Essays Biochem. 2005; 41:205-18.
    View in: PubMed
    Score: 0.077
  222. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004 Dec 01; 64(23):8746-53.
    View in: PubMed
    Score: 0.077
  223. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76.
    View in: PubMed
    Score: 0.077
  224. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004 Nov 15; 10(22):7540-6.
    View in: PubMed
    Score: 0.077
  225. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004 Oct 15; 64(20):7500-6.
    View in: PubMed
    Score: 0.076
  226. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93.
    View in: PubMed
    Score: 0.076
  227. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004 Nov 01; 104(9):2886-92.
    View in: PubMed
    Score: 0.075
  228. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004 Oct 15; 104(8):2458-66.
    View in: PubMed
    Score: 0.075
  229. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
    View in: PubMed
    Score: 0.074
  230. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52.
    View in: PubMed
    Score: 0.074
  231. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15; 103(8):3158-66.
    View in: PubMed
    Score: 0.072
  232. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36.
    View in: PubMed
    Score: 0.072
  233. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene. 2003 Nov 27; 22(54):8797-801.
    View in: PubMed
    Score: 0.072
  234. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. 2004 May 01; 103(9):3474-9.
    View in: PubMed
    Score: 0.072
  235. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003 Nov 20; 22(52):8386-93.
    View in: PubMed
    Score: 0.072
  236. Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003 Oct 01; 63(19):6187-94.
    View in: PubMed
    Score: 0.071
  237. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 Sep 15; 63(18):5850-8.
    View in: PubMed
    Score: 0.071
  238. Novel therapeutic approaches for multiple myeloma. Immunol Rev. 2003 Aug; 194:164-76.
    View in: PubMed
    Score: 0.070
  239. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
    View in: PubMed
    Score: 0.070
  240. Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol. 2003 Jun; 7(2):191-204.
    View in: PubMed
    Score: 0.069
  241. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May; 121(4):592-6.
    View in: PubMed
    Score: 0.069
  242. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003 Aug 15; 102(4):1435-42.
    View in: PubMed
    Score: 0.069
  243. Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):309-12.
    View in: PubMed
    Score: 0.069
  244. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62.
    View in: PubMed
    Score: 0.068
  245. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21.
    View in: PubMed
    Score: 0.067
  246. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003 May 01; 101(9):3606-14.
    View in: PubMed
    Score: 0.067
  247. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80.
    View in: PubMed
    Score: 0.067
  248. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9.
    View in: PubMed
    Score: 0.067
  249. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003 Feb 15; 101(4):1530-4.
    View in: PubMed
    Score: 0.066
  250. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002 Sep 15; 100(6):2187-94.
    View in: PubMed
    Score: 0.066
  251. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003 Jan 15; 101(2):703-5.
    View in: PubMed
    Score: 0.066
  252. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002 Sep 01; 62(17):4996-5000.
    View in: PubMed
    Score: 0.066
  253. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
    View in: PubMed
    Score: 0.066
  254. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83.
    View in: PubMed
    Score: 0.066
  255. Novel biologically based therapies for multiple myeloma. Int J Hematol. 2002 Aug; 76 Suppl 1:340-1.
    View in: PubMed
    Score: 0.066
  256. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. . 2002 Aug; 1(10):851-60.
    View in: PubMed
    Score: 0.066
  257. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82.
    View in: PubMed
    Score: 0.065
  258. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30.
    View in: PubMed
    Score: 0.065
  259. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86.
    View in: PubMed
    Score: 0.065
  260. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. . 2002 May; 1(7):539-44.
    View in: PubMed
    Score: 0.064
  261. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47.
    View in: PubMed
    Score: 0.064
  262. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002 Feb 21; 21(9):1346-58.
    View in: PubMed
    Score: 0.064
  263. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol. 2021 Nov; 23(11):1199-1211.
    View in: PubMed
    Score: 0.062
  264. Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. Clin Cancer Res. 2021 Sep 13.
    View in: PubMed
    Score: 0.062
  265. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021 Aug; 194(3):496-507.
    View in: PubMed
    Score: 0.060
  266. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 10; 21(10):1317-1330.
    View in: PubMed
    Score: 0.057
  267. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 09 20; 38(27):3107-3118.
    View in: PubMed
    Score: 0.057
  268. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
    View in: PubMed
    Score: 0.057
  269. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
    View in: PubMed
    Score: 0.056
  270. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biol Blood Marrow Transplant. 2020 08; 26(8):1414-1424.
    View in: PubMed
    Score: 0.056
  271. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 12 07; 394(10214):2096-2107.
    View in: PubMed
    Score: 0.054
  272. A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clin Cancer Res. 2020 01 15; 26(2):344-353.
    View in: PubMed
    Score: 0.054
  273. Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 03 26; 9(4):39.
    View in: PubMed
    Score: 0.052
  274. Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149.
    View in: PubMed
    Score: 0.052
  275. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486.
    View in: PubMed
    Score: 0.050
  276. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018 12 06; 132(23):2456-2464.
    View in: PubMed
    Score: 0.050
  277. Meaningful changes in end-of-life care among patients with myeloma. Haematologica. 2018 08; 103(8):1380-1389.
    View in: PubMed
    Score: 0.049
  278. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
    View in: PubMed
    Score: 0.049
  279. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635.
    View in: PubMed
    Score: 0.048
  280. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
    View in: PubMed
    Score: 0.048
  281. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol. 2017 12; 179(5):756-771.
    View in: PubMed
    Score: 0.047
  282. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
    View in: PubMed
    Score: 0.046
  283. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3279-3289.
    View in: PubMed
    Score: 0.046
  284. Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017 Sep 01; 35(25):2911-2918.
    View in: PubMed
    Score: 0.046
  285. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):555-562.
    View in: PubMed
    Score: 0.046
  286. Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Sep 12; 8(39):66641-66655.
    View in: PubMed
    Score: 0.046
  287. Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Jun 08.
    View in: PubMed
    Score: 0.046
  288. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 04 06; 376(14):1311-1320.
    View in: PubMed
    Score: 0.045
  289. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017 04; 18(4):e206-e217.
    View in: PubMed
    Score: 0.045
  290. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13162-13167.
    View in: PubMed
    Score: 0.044
  291. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346.
    View in: PubMed
    Score: 0.043
  292. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol. 2016 Sep; 174(5):711-20.
    View in: PubMed
    Score: 0.043
  293. Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214.
    View in: PubMed
    Score: 0.042
  294. Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. Br J Haematol. 2016 Apr; 173(1):82-8.
    View in: PubMed
    Score: 0.042
  295. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2039-2051.
    View in: PubMed
    Score: 0.041
  296. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33(26):2863-9.
    View in: PubMed
    Score: 0.040
  297. Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov. 2015 Sep; 5(9):972-87.
    View in: PubMed
    Score: 0.040
  298. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13; 373(7):621-31.
    View in: PubMed
    Score: 0.040
  299. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015 Apr; 90(4):314-9.
    View in: PubMed
    Score: 0.039
  300. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015 03 26; 125(13):2068-74.
    View in: PubMed
    Score: 0.039
  301. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov; 15(12):e538-48.
    View in: PubMed
    Score: 0.038
  302. Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC Genomics. 2014 Oct 17; 15:904.
    View in: PubMed
    Score: 0.038
  303. Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7.
    View in: PubMed
    Score: 0.038
  304. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
    View in: PubMed
    Score: 0.037
  305. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014 Jun; 20(6):599-606.
    View in: PubMed
    Score: 0.037
  306. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
    View in: PubMed
    Score: 0.037
  307. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014 Mar; 15(3):333-42.
    View in: PubMed
    Score: 0.036
  308. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20; 32(6):587-600.
    View in: PubMed
    Score: 0.036
  309. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997.
    View in: PubMed
    Score: 0.036
  310. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014 Jan 30; 123(5):632-9.
    View in: PubMed
    Score: 0.036
  311. Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets. Semin Oncol. 2013 Oct; 40(5):537-48.
    View in: PubMed
    Score: 0.036
  312. Phase transitions in human IgG solutions. J Chem Phys. 2013 Sep 28; 139(12):121904.
    View in: PubMed
    Score: 0.036
  313. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
    View in: PubMed
    Score: 0.035
  314. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 2013 May; 71(5):1357-68.
    View in: PubMed
    Score: 0.034
  315. Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. Biol Blood Marrow Transplant. 2013 Jun; 19(6):858-9.
    View in: PubMed
    Score: 0.034
  316. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013 Feb 21; 121(8):1296-303.
    View in: PubMed
    Score: 0.034
  317. Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol. 2012 Nov; 159(3):340-51.
    View in: PubMed
    Score: 0.033
  318. Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13359-61.
    View in: PubMed
    Score: 0.033
  319. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
    View in: PubMed
    Score: 0.032
  320. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
    View in: PubMed
    Score: 0.032
  321. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther. 2012 Apr; 11(4):942-51.
    View in: PubMed
    Score: 0.032
  322. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
    View in: PubMed
    Score: 0.031
  323. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
    View in: PubMed
    Score: 0.031
  324. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS One. 2011; 6(7):e20226.
    View in: PubMed
    Score: 0.030
  325. Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica. 2011 Aug; 96(8):1170-9.
    View in: PubMed
    Score: 0.030
  326. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
    View in: PubMed
    Score: 0.030
  327. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 09; 117(23):6063-73.
    View in: PubMed
    Score: 0.030
  328. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics. 2011 Apr; 11(8):1391-402.
    View in: PubMed
    Score: 0.030
  329. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-19.
    View in: PubMed
    Score: 0.030
  330. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5.
    View in: PubMed
    Score: 0.030
  331. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
    View in: PubMed
    Score: 0.029
  332. Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. Clin Chim Acta. 2011 Mar 18; 412(7-8):562-8.
    View in: PubMed
    Score: 0.029
  333. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
    View in: PubMed
    Score: 0.029
  334. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20; 28(33):4976-84.
    View in: PubMed
    Score: 0.029
  335. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep; 85(9):670-4.
    View in: PubMed
    Score: 0.029
  336. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res. 2010 Jun 15; 16(12):3260-9.
    View in: PubMed
    Score: 0.028
  337. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
    View in: PubMed
    Score: 0.028
  338. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
    View in: PubMed
    Score: 0.028
  339. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May; 149(4):537-49.
    View in: PubMed
    Score: 0.028
  340. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1422-8.
    View in: PubMed
    Score: 0.028
  341. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
    View in: PubMed
    Score: 0.028
  342. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
    View in: PubMed
    Score: 0.028
  343. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica. 2010 Jul; 95(7):1144-9.
    View in: PubMed
    Score: 0.027
  344. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60.
    View in: PubMed
    Score: 0.027
  345. In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6.
    View in: PubMed
    Score: 0.027
  346. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15; 69(14):5835-42.
    View in: PubMed
    Score: 0.026
  347. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Aug 27; 114(9):1729-35.
    View in: PubMed
    Score: 0.026
  348. Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009 Mar; 67(3):593-601.
    View in: PubMed
    Score: 0.026
  349. Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31.
    View in: PubMed
    Score: 0.025
  350. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28; 359(9):906-17.
    View in: PubMed
    Score: 0.025
  351. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(2):222-9.
    View in: PubMed
    Score: 0.025
  352. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(1):46-53.
    View in: PubMed
    Score: 0.025
  353. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74.
    View in: PubMed
    Score: 0.024
  354. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 2007 Oct 15; 13(20):6162-7.
    View in: PubMed
    Score: 0.023
  355. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res. 2007 Jul 01; 13(13):3771-5.
    View in: PubMed
    Score: 0.023
  356. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96.
    View in: PubMed
    Score: 0.022
  357. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul; 91(7):929-34.
    View in: PubMed
    Score: 0.021
  358. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005 Dec 01; 106(12):3777-84.
    View in: PubMed
    Score: 0.020
  359. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005 Mar 15; 103(6):1195-200.
    View in: PubMed
    Score: 0.020
  360. Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood. 2005 Mar 01; 105(5):2235-8.
    View in: PubMed
    Score: 0.019
  361. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 01; 103(5):1787-90.
    View in: PubMed
    Score: 0.018
  362. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol. 2003 Jun; 121(6):842-8.
    View in: PubMed
    Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.